In chronic hypercalcemia, inhibition of thick ascending limb sodium chloride reabsorption is mediated by elevated intrarenal PGE 2 . The mechanisms and source of elevated PGE 2 in hypercalcemia are not known. We determined the effect of hypercalcemia on intrarenal expression of cytosolic phospholipase A 2 (cPLA 2 ), prostaglandin H synthase-1 (PGHS-1), and prostaglandin H synthase-2 (PGHS-2), enzymes important in prostaglandin production. In rats fed dihydrotachysterol to induce hypercalcemia, Western blot analysis revealed significant upregulation of both cPLA 2 and PGHS-2 in the kidney cortex and the inner and outer medulla. Immunofluorescence localized intrarenal cPLA 2 and PGHS-2 to interstitial cells of the inner and outer medulla, and to macula densa and cortical thick ascending limbs in both control and hypercalcemic rats. Hypercalcemia had no effect on intrarenal expression of PGHS-1. To determine if AT 1 angiotensin II receptor activation was involved in the stimulation of cPLA 2 and PGHS-2 in hypercalcemia, we treated rats with the AT 1 receptor antagonist, losartan. Losartan abolished the polydipsia associated with hypercalcemia, prevented the increase in cPLA 2 protein in all regions of the kidney, and diminished PGHS-2 expression in the inner medulla. In addition, losartan completely prevented the increase in urinary PGE 2 excretion in hypercalcemic rats. Intrarenal levels of angiotensin II were unchanged in hypercalcemia. These data indicate that hypercalcemia stimulates intrarenal cPLA 2 and PGHS-2 protein expression. Our results further support a role for angiotensin II, acting on AT 1 receptors, in mediating this stimulation. (
Introduction
The association of hypercalcemia with disturbances in renal concentrating ability, water intake, and loop of Henle function has been widely recognized in both humans (1, 2) and experimental animals (3, 4) . Studies in rats show that chronic hypercalcemia is associated with inhibition of thick ascending limb NaCl reabsorption (5) . Renal PGE 2 excretion is strikingly elevated in hypercalcemic rats (6, 7) , suggesting that PGE 2 may be involved in mediating this defective NaCl reabsorption. In rats with vitamin D-induced chronic hypercalcemia, outer medullary PGE 2 levels are increased, and PGE 2 appears to mediate the inhibition of thick ascending limb NaCl transport at a step proximal to the generation of cAMP (8) .
Although differences exist between animal species, PGE 2 is the predominant (80-90% of the measured prostaglandins) renal prostaglandin in all species. The proximal and distal convoluted tubules synthesize very small amounts of PGE 2 , while the thin descending limb of Henle, the medullary thick ascending limb of Henle, and the medullary and cortical collecting tubules possess greater synthetic capacity (9, 10) . Medullary interstitial cells are also able to produce abundant amounts of PGE 2 (11) .
The availability of arachidonic acid is a rate-limiting step controlling the synthesis of prostaglandins. Release of arachidonic acid from membrane phospholipids is regulated primarily by phospholipase A 2 , an enzyme that catalyzes hydrolysis of the ester linkage at the sn -2 position of membrane phospholipids to produce free fatty acids and lysophospholipids. A high molecular mass (85-kD) cytosolic phospholipase A 2 (cPLA 2 ) 1 has been identified in numerous tissues, including rat kidney (12) . Prostaglandin H synthase (PGHS) is another key enzyme involved in prostaglandin synthesis. PGHS exhibits both bisoxygenase (cyclooxygenase) activity catalyzing prostaglandin G 2 formation from arachidonic acid, and peroxidase activity, which reduces the 15-hydroperoxyl group of prostaglandin G 2 to the 15-OH of prostaglandin H 2 . Mammalian cells contain two isoforms of PGHS (PGHS-1 and PGHS-2), which share ‫ف‬ 60% amino acid identity within the same species (13) .
PGHS-1 mediates basal production of PGE 2 (14) , and within the mouse kidney is constitutively expressed in arteries and arterioles, glomeruli, collecting ducts, and medullary interstitial cells, with no immunoreactivity detected in proximal or distal convoluted tubules, loop of Henle, or macula densa (15, 16) . PGHS-2 has been termed the inducible form of the enzyme since its expression is often undetectable unless induced by mitogenic or proinflammatory agents (17) (18) (19) (20) (21) . In the kidney, however, Harris et al. detected PGHS-2 immunoreactivity in the absence of inflammation, in the macula densa, cortical thick ascending limb, and interstitial cells of the inner medulla, with no immunoreactivity in arterioles, glomeruli, or collecting ducts (15) .
The source and mechanisms for elevated renal PGE 2 levels in hypercalcemia are unknown. In this study, we used Western blot analysis and immunofluorescence to determine the effect of hypercalcemia on protein expression of cPLA 2 , PGHS-1, and PGHS-2 in the rat kidney. Our results reveal that hypercalcemia stimulates expression of cPLA 2 and PGHS-2 in kidney cortex, and in inner and outer medulla. Furthermore, our data suggest a key role for activation of the AT 1 angiotensin II (Ang II) receptor in mediating hypercalcemia-induced stimulation of cPLA 2 and PGHS-2 expression.
Methods
Animals. Male Sprague-Dawley rats (250-320 g) were used for this study. Hypercalcemia was induced by feeding the rats a normal electrolyte diet containing 4.25 mg/kg diet of dihydrotachysterol (DHT) for 1-5 d, as previously described (5) . Control measurements were taken from rats pair-fed (7 g/100 g body wt./d) the identical electrolyte diet without DHT. All animals were allowed free access to water. In some studies, hypercalcemic and control rats were given losartan (15 mg/kg/d) (22) in the drinking water. At a predetermined time during the study period, rats were anesthetized with Somnitol (60 mg/ kg i.p.), and cardiac puncture was performed to obtain blood for measurement of ionized calcium and pH by ion-specific electrodes (Stat Analyzer™ model 634; Ciba Corning, Medfield, MA). Reported blood calcium was corrected to pH 7. 40 .
Western blot analysis. One kidney was rapidly removed and immediately placed in 4 Њ C homogenization buffer (50 mM Hepes [pH 7.4], 250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 10 g/ml leupeptin, 10 g/ml aprotinin, 10% vol/vol glycerol). The kidneys were decapsulated and cut into 1-mm slices. The inner medulla, outer medulla, and cortex were dissected from each slice, separated, placed into fresh buffer, and homogenized for 30 s using a polytron. Tissue homogenates were centrifuged at 10,000 g for 5 min, and protein concentrations of the supernatants were measured using the Bradford assay (23) with BSA as standard. Total protein equivalents for each lysate (5-g inner medulla; 10-g outer medulla, and 20-g cortex) were heated at 100 Њ C for 5 min in sample buffer containing 63 mM Tris-HCl, pH 6.8, 4% (wt/vol) SDS, 20% (vol/vol) glycerol, 2% mercaptoethanol, and 1 mg/ml of bromophenol blue. The samples were separated on 7.5% SDS/polyacrylamide minigels using the Mini PROTEAN II electrophoretic apparatus, and transferred to nitrocellulose membranes using the Mini Trans blot electrophoretic transfer system (Bio-Rad Laboratories, Mississauga, Ontario, Canada). Membranes were blocked overnight at room temperature with a solution of 5% fat-free dried milk in Tris-buffered saline-0.1% Tween-20 (TBS-T). Separate membranes were incubated at room temperature with either a polyclonal PGHS-1 rabbit IgG (1:1000 dilution) for 18 h, a rabbit anti-murine polyclonal antibody to PHGS-2 (1:1000 dilution) for 18 h, or with polyclonal cPLA 2 antiserum for 1 h (1:2000 dilution). The membranes were washed with TBS-T and incubated with goat anti-rabbit IgG conjugated to horseradish peroxidase (1:2000 dilution) for 30 min at room temperature. Immunoreactive proteins were visualized on x-ray film, using the enhanced chemiluminescence method.
Immunohistochemistry. Kidneys were removed, immediately fixed in 10% formalin, embedded in paraffin, and sections (4-m) were mounted on glass slides. For immunostaining, the sections were permeabilized with SDS followed by incubation with 1% BSA to minimize nonspecific antibody binding. The sections were then incubated for 24 h at 4 Њ C with either the polyclonal cPLA 2 antiserum (1:100 dilution) or the rabbit anti-murine antiserum (1:50 dilution) for PGHS-2 immunolocalization. All sections were also incubated with a polyclonal rabbit anti-mouse antibody to bNOS (1:100 dilution), known to localize to the macula densa (24 
Measurement of intrarenal Ang II.
Rats were fed the control or DHT-containing diet for 3 d, and intrarenal levels of Ang II were measured by HPLC and radioimmunoassay using the method of Ruzicka et al. (25) . In brief, kidneys were perfused in situ via intracardiac injection with PBS (pH 7.4) to remove blood, and were then removed and snap-frozen in liquid nitrogen. Snap-frozen kidneys were weighed, minced, and then boiled for 20 min in 1 M acetic acid. Tissue was then homogenized for 1 min using a hand-held homogenizer (Tissue Tearor™; Biospec Products Inc., Racine, WI), and centrifuged at 10,000 g for 10 min at 4 Њ C. The aqueous phase was removed, passed through a C18 Sep-Pak cartridge (Waters, Milford, MA), and eluted with 4% acetic acid in ethanol. Eluants were dried in a Speed Vac concentrator for further analysis. HPLC separation of Ang II was kindly performed by the laboratory of Dr. F. Leenen (University of Ottawa), according to their published protocol (25) . After HPLC, Ang II levels were measured in the eluants by radioimmunoassay, using [ Densitometric and statistical analyses. The intensity of bands obtained from Western blot analysis was quantified by scanning densitometry using a software image analysis program (Image 1.47). Protein bands from hypercalcemic rats were compared to the intensity of proteins from pair-fed control rats. An arbitrary density of one was assigned to the band from the control rat kidney. Preliminary experiments revealed that band intensity on autoradiographs for cPLA 2 , PGHS-1, and PGHS-2 increased linearly with quantity of protein loaded (not shown).
Data are expressed as means Ϯ SE. Significance was assigned at P Ͻ 0.05. Since protein bands from hypercalcemic rats were normalized to bands from control rats, the data do not follow a normal distribution. Therefore, statistical analysis of the Western blots was performed using the nonparametric Kruskal-Wallis test in combination with the Dunn's multiple comparison post-hoc test to examine the differences between individual group means. All other data were analyzed using a one-way ANOVA followed by the Tukey post-hoc test.
Materials. Normal electrolyte diet with and without DHT was obtained from ICN Nutritional Biochemicals (Cleveland, OH); 
Results
Hypercalcemia was induced by feeding rats a DHT-containing diet. Blood-ionized calcium concentration, presented in Table I , was significantly elevated after 2 d of diet (control, 1.33 Ϯ 0.03 mmol/liter vs. DHT, 1.52 Ϯ 0.01 mmol/liter; P Ͻ 0.01, n ϭ 4) and increased to a maximum on day 3 (1.65 Ϯ 0.05 mmol/liter; P Ͻ 0.001 vs. day 0; n ϭ 4). Levels remained significantly elevated in DHT-fed rats for the remainder of the study period (1.69 Ϯ 0.02 mmol/liter, day 5; P Ͻ 0.001 vs. day 0; n ϭ 5). To determine whether intrarenal expression of PGHS-1, PGHS-2, and cPLA 2 is affected by hypercalcemia, Western blots were performed on homogenates of inner medulla, outer medulla, and cortex from rats fed the DHT-containing diet for up to 5 d.
PGHS-1. PGHS-1 protein was detected on Western blots as a single band of ‫ف‬ 75 kD in kidneys from both control and hypercalcemic rats. There was no significant change in expression of this protein with hypercalcemia over the period studied in any of the kidney regions (Fig. 1) . PGHS-2. PGHS-2 was expressed in kidneys from both control and hypercalcemic rats, and appeared as a single band on most blots at ‫ف‬ 72 kD. PGHS-2 protein expression in both inner and outer medulla was significantly increased after 3 d on the DHT diet (fold increase vs. control: inner medulla, 1.8Ϯ0.2; P Ͻ 0.05, n ϭ 3; outer medulla, 2.3Ϯ0.2; P Ͻ 0.05, n ϭ 3), after which expression returned to control levels (Fig. 2, A and  B) . PGHS-2 expression in the cortex (Fig. 2 C) was also increased on day 3 (fold increase vs. control: 15.7Ϯ7.9; P Ͻ 0.01, n ϭ 6) and remained significantly elevated up to day 5.
cPLA 2 . Using a specific antiserum for cPLA 2 , an immunoreactive protein of ‫ف‬ 110 kD was observed (Fig. 3) . In the inner medulla, outer medulla, and cortex, there were significant increases in cPLA 2 protein expression at 3 d on the DHT diet (fold increase vs. control: inner medulla, 2.7Ϯ0.7; P Ͻ 0.01, n ϭ 4; outer medulla, 1.5Ϯ0.3; P Ͻ 0.05, n ϭ 6; cortex, 1.6Ϯ0.2; P Ͻ 0.05, n ϭ 6). Levels of cPLA 2 protein in the outer medulla at days 4 and 5 of DHT diet were not statistically different from control values. cPLA 2 protein expression in the inner medulla and cortex, however, remained significantly increased at days 4 and 5 of the study.
Immunohistochemistry. To determine which cells might mediate the changes in expression of PGHS-2 and cPLA 2 in hypercalcemia, immunofluorescence studies were performed. Intrarenal localization of PGHS-2 and cPLA 2 by immunohistochemistry did not differ between control and hypercalcemic rats. PGHS-2 immunoreactivity in the inner and outer medulla was localized primarily to interstitial cells (Fig. 4, A and B) . In the cortex, intense staining for PGHS-2 was observed in the macula densa region, as identified by colocalization with bNOS (24) , and in the adjoining cortical thick ascending limb (Fig. 4, C, D, and E) .
In the inner medulla, cPLA 2 immunoreactivity was detected mainly in the interstitial cells with a faint signal in epithelial cells of the inner medullary collecting ducts (Fig. 5 A) . The interstitial cells of the outer medulla also showed positive immunoreactivity for cPLA 2 (Fig. 5 B) . In the cortex, cPLA 2 immunoreactivity was detected in the macula densa region (Fig. 5, C, D, and E) .
Role of AT 1 Ang II receptors. Ang II has been reported to increase prostaglandin production in a number of systems (26) (27) (28) . In our previous studies, circulating plasma renin levels did not increase significantly in hypercalcemic rats with access to water, although pair-water feeding was associated with significantly higher levels (5). Studies were performed to investigate the effect of hypercalcemia on intrarenal levels of Ang II, determined by HPLC and radioimmunoassay. After 3 d of hypercalcemia, a time point at which we observed increased expression of cPLA 2 and PGHS-2, levels of intrarenal Ang II did not significantly differ from control values (Fig. 6) . These values were comparable to those previously reported (29) .
To determine whether AT 1 Ang II receptor activation plays a role in the regulation of cPLA 2 and PGHS-2 in hypercalcemia, losartan, a specific AT 1 Ang II receptor antagonist, was administered in the drinking water of rats on control and DHT diets for 3 d, a time at which these proteins were significantly elevated in hypercalcemia (Figs. 2 and 3) . Losartan had no effect on serum calcium in hypercalcemic rats (hypercalcemic, 1.62Ϯ0.05 mmol/liter vs. hypercalcemic ϩ losartan, 1.61Ϯ0.06 mmol/liter; P ϭ NS, n ϭ 5). Water intake of all animals was measured daily, and the dose of losartan was adjusted to ensure that 15 mg/kg/d was being administered. Water intake was significantly increased in hypercalcemic animals (control, 19.6Ϯ1.4 ml/100 g body wt/d vs. hypercalcemic, 27.4Ϯ2.3 ml/ 100 g body wt/d; P Ͻ 0.05, n ϭ 5) in agreement with previous studies (5, 6) . Treatment of hypercalcemic animals with losartan, however, significantly reduced water intake (hypercalcemic ϩ losartan, 20.4Ϯ1.1 ml/100 g body wt/d; P ϭ NS vs. control, n ϭ 11) (Fig. 7) .
As shown in Fig. 8 , in rats on control diet, cPLA 2 protein expression was not affected by losartan. In hypercalcemic rats, however, losartan treatment significantly inhibited the increase in cPLA 2 protein in the inner medulla, outer medulla, and cortex. Losartan also abolished the increase in PGHS-2 expression in the inner medulla of hypercalcemic rats, but had no effect on increased expression of PGHS-2 in the cortex and outer medulla (Fig. 9) .
Urinary excretion of PGE 2 between days 2 and day 3 did not differ significantly between control and hypercalcemic rats (control, 417Ϯ116 ng/d vs. hypercalcemic, 535Ϯ193 ng/d; P ϭ NS, n ϭ 4). In contrast, and in agreement with previous reports (6, 7), urinary PGE 2 excretion measured at 5 d was significantly elevated in hypercalcemic rats when compared with controls (control, 347Ϯ22 ng/d vs. hypercalcemic, 1706Ϯ210 ng/d; P Ͻ 0.001, n ϭ 3) (Fig. 10) . In hypercalcemic rats treated with losartan, however, the increase in urinary PGE 2 was completely prevented (hypercalcemic ϩ losartan, 705Ϯ119 ng/d; P ϭ NS vs. control, n ϭ 4).
Discussion
Inhibition of thick ascending limb chloride reabsorption in hypercalcemia has been linked to increased prostaglandin levels in the kidney (8) . There have been no studies, however, addressing either regulation of enzymes involved in prostaglandin synthesis or determination of the source of increased prostaglandins in hypercalcemia. The results from this study demonstrate that hypercalcemia causes upregulation of intrarenal cPLA 2 and PGHS-2, the two major enzymes involved in prostaglandin synthesis, without altering intrarenal localization, as determined by immunofluorescence. Furthermore, we have demonstrated a role for Ang II, acting on AT 1 receptors, in mediating this upregulation, and in increasing urinary PGE 2 excretion in hypercalcemia. In DHT-induced hypercalcemia, blood calcium levels are significantly elevated by 2 d, as is water intake, two events that are independent of, and not responsible for, the concentrating defect that is evident by day 3 (6) . The concentrating defect has been shown to be mediated by intrarenal PGE 2 , levels that are significantly elevated in hypercalcemia (8) . A possible mechanism for this defect is suggested by the recent study of Kaji et al. (30) , who demonstrated that PGE 2 inhibits Na-K-2Cl cotransport in medullary thick ascending limb cells by downregulating the number of functioning cotransporters.
The rate-limiting step in prostaglandin synthesis is the PLA 2 -mediated release of arachidonic acid from membrane phospholipids (31) . cPLA 2 has been isolated and purified from kidney tissue (12) , and its activity has been studied in isolated glomerular mesangial cells (32). In vivo regulation of renal cPLA 2 and its specific cellular localization in the kidney, however, remains unclear. In this work, expression of cPLA 2 was evident in normal rat kidney tissue, and we demonstrated significant upregulation after 3 d of DHT treatment, suggesting increased endogenous availability of arachidonic acid in the kidneys of these animals. In addition, we localized immunoreactive cPLA 2 , mainly to interstitial cells of the inner and outer medulla (which are well known to synthesize and release prostaglandins [33, 34] ) and to the macula densa.
Induction of PGHS-2, the other critical enzyme involved in prostaglandin synthesis, is associated with inflammation, mitogenesis, and ovulation (13, 35) . Expression of PGHS-2 mRNA in vitro parallels that of c-fos, leading to the classification of PGHS-2 as an immediate early response gene (36) . Rapid transient activation of PGHS-2, and subsequent return to baseline levels, has been observed in a variety of cultured cell systems (18, 37) including kidney mesangial cells (34) . To date, however, renal expression and regulation of this enzyme in vivo has not been fully elucidated. PGHS-2 is expressed under unstimulated conditions in the kidney (15); our work provides further support for this finding. In addition, we demonstrate that the expression pattern of PGHS-2 in this in vivo model is consistent with observations in cultured cells. To this end, we report that PGHS-2 protein expression was significantly and maximally increased in hypercalcemic animals after 3 d of ingestion of DHT-containing diet, and displayed a similar cellular pattern of distribution to cPLA 2 . Unlike cPLA 2 , however, PGHS-2 protein levels in the inner and outer medulla decrease after the initial stimulation on day 3, suggesting that cPLA 2 , which is still stimulated at this time, is responsible for increasing PGE 2 production in these regions. In the cortex of hypercalcemic animals, however, levels of PGHS-2 remained significantly elevated until day 5, suggesting that the presence of additional regulatory signals or factors for PGHS-2 expression (in the macula densa and cortical thick ascending limb cells) differ from those influencing interstitial cells of the inner and outer medulla.
PGHS-1 is expressed constitutively in almost all tissues including kidney (15, 16) . In this work, we found that PGHS-1 protein levels remained unchanged with hypercalcemia in all kidney regions. Previous studies reveal that PGHS-1 functions primarily as a housekeeping protein (14). Thus, it appears that in hypercalcemia, PGHS-1 preserves its role as a constitutive protein, responsible for the basal production of prostaglandins, which are most likely involved in the rapid response to stimulation by agonists.
The effects observed in this study are likely due to increased plasma calcium levels, and not due to direct effects of vitamin D in the kidney. Receptors for vitamin D have been localized predominantly to the distal convoluted tubule, connecting segment, initial cortical collecting duct, and proximal tubule (38) , regions in which we detected no appreciable immunoreactivity for cPLA 2 or PGHS-2.
Ang II has been reported to stimulate PGE 2 production in kidney tubular epithelial cells, mesangial cells, and interstitial cells (26, 27) . Siragy and Carey recently demonstrated that losartan, an AT 1 receptor antagonist, blocked the increase in renal interstitial fluid PGE 2 levels resulting from both sodium depletion and administration of Ang II (28) . In vascular smooth muscle cells, Ang II induces phosphorylation of PLA 2 and increases its activity (39) . We investigated the possibility that AT 1 receptor activation occurs in hypercalcemia, and mediates the observed effects. Our data strongly support this hypothesis. First, these studies demonstrate that increased water intake, which is consistently observed in hypercalcemic rats (5, 8, 40) , was abolished by administration of losartan, suggesting that polydipsic behavior in hypercalcemia is mediated by binding of Ang II to the AT 1 receptor. Second, losartan prevented the increase in cPLA 2 expression in hypercalcemic animals in all kidney regions, and inhibited increased PGHS-2 expression in the inner medulla without affecting expression in the cortex and outer medulla. Finally, we demonstrate that losartan completely inhibited the increase in urinary PGE 2 excretion observed in rats with hypercalcemia for 5 d. We did not observe any change in urinary PGE 2 levels on day 3, a time when both cPLA 2 and PGHS-2 were stimulated. Thus, there appears to be a lag time between stimulation of expression of these enzymes and the appearance of increased urinary excretion of PGE 2 . Previous studies have established that urinary levels of PGE 2 reflect intrarenal synthesis, derived mainly from the inner medulla (41) . Taken together, these data suggest that stimulation of cPLA 2 expression, through Ang II activation of the AT 1 receptor in the inner medulla, largely mediates increased PGE 2 excretion in hypercalcemic animals.
Plasma renin activity is not increased significantly in hypercalcemic rats allowed free access to water (5, 6) . Furthermore, our data indicate that intrarenal Ang II levels, measured at a time when expression of cPLA 2 and PGHS-2 was increased, are also unchanged with hypercalcemia. This finding suggests that affinity of Ang II for AT 1 receptors or AT 1 receptor number may be stimulated with hypercalcemia. Our data do not, however, permit precise intrarenal localization of sites of action of Ang II in hypercalcemia. Specific binding sites for Ang II (42) and AT 1 receptor mRNA (43) have been detected in all tubular segments, suggesting that Ang II may bind to receptors on cortical and medullary thick ascending limb segments, and Figure 9 . Effect of losartan on PGHS-2 protein expression in hypercalcemia. Representative Western blots (left) and densitometric analyses (right) of protein expression obtained from rats fed the control diet alone (C), the control diet with losartan in the drinking water (C ϩ LOS), the DHT-containing diet (HC), and the DHT-containing diet and losartan in the drinking water (HC ϩ LOS) for 3 d. (A) Inner medulla (5 g protein/well), (B) outer medulla (10 g protein/ well), and (C) cortex (20 g protein/well). *P Ͻ 0.05 vs. control; **P Ͻ 0.01 vs. control. Figure 10 . Effect of losartan on PGE 2 excretion. Urine was collected over a 24-h period (day 4 to day 5) from rats fed the control diet (C) alone, the control diet with losartan in the drinking water (C ϩ LOS), the DHT-containing diet (HC), and the DHT-containing diet and losartan in the drinking water (HC ϩ LOS). PGE 2 was measured by radioimmunoassay as described in Methods. Data are expressed as meansϮSE. **P Ͻ 0.001 vs. C, C ϩ LOS, and HC ϩ LOS. thereby directly stimulate cPLA 2 protein expression. We cannot, however, rule out the possibility that Ang II mediates its effects in an indirect fashion by altering intrarenal hemodynamics.
In this study, cPLA 2 immunoreactivity was detected in interstitial cells of the inner and outer medulla. Zhou et al. have detected Ang II binding sites in type-1 interstitial cells of the inner stripe of the outer medulla, by electron microscopic emulsion autoradiography (44) . By autoradiography, this group was unable to detect Ang II binding sites in the inner medulla, although AT 1 Ang II receptor mRNA has been localized to inner medullary collecting duct by reverse transcription PCR (43). Thus, since we also localized cPLA 2 to cells of the inner medullary collecting duct, it is possible that intrarenal expression of this protein with hypercalcemia is partly due to AT 1 receptor stimulation on inner medullary collecting duct cells. Similarly, although PGHS-2 protein expression was stimulated in all regions of the kidney by hypercalcemia in this study, losartan abrogated only the expression in the inner medulla. Since PGHS-2 was immunolocalized only to interstitial cells of the inner medulla, the results suggest the possibility that these cells do indeed contain AT 1 Ang II receptors, or that alteration in renal blood flow mediates the effects of Ang II.
In summary, hypercalcemia upregulates intrarenal cPLA 2 and PGHS-2 protein expression, two proteins critical in the synthesis of prostaglandins. Our data suggest that enhanced expression of cPLA 2 in the inner medulla may account for the elevated urinary PGE 2 levels in hypercalcemia. Furthermore, we have demonstrated an important role for Ang II, acting on AT 1 receptors, in mediating hypercalcemia-induced stimulation of intrarenal cPLA 2 and PGHS-2 expression, and in increasing renal PGE 2 production.
